or Try an Advanced Search...

    Metastatic Colorectal Cancer Stocks List

    Symbol Grade Name % Change
    CRDF D Cardiff Oncology, Inc. -0.20
    NKTR F Nektar Therapeutics -0.18
    REGN F Regeneron Pharmaceuticals, Inc. 0.15
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research
    Related Stock Lists: Colorectal Cancer Biopharmaceutical Biotechnology Clinical Development Drugs Immunology Medicine Nektar Therapeutics Pain Pharmaceutical Acute Myeloid Leukemia Acute Pain Adenosine Advanced Solid Tumors Aminoglycoside Angiogenesis Anti Infectives Antibiotics Antibodies Antineoplastic Drugs

    Related ETFs - A few ETFs which own one or more of the above listed Metastatic Colorectal Cancer stocks.

    Symbol Grade Name Weight
    BBH D Market Vectors Biotech ETF 6.9
    IBBQ D Invesco Nasdaq Biotechnology ETF 5.67
    IBB D iShares Nasdaq Biotechnology Index Fund 5.67
    CANC D Tema Oncology ETF 5.25
    BIS B ProShares UltraShort Nasdaq Biotechnology 4.61
    View all Metastatic Colorectal Cancer ETFs...
    Compare ETFs
    Compare BBH to CANC Compare IBBQ to BIS Compare IBBQ to CANC

        Metastatic Colorectal Cancer Stocks Recent News

        Date Stock Title
        Nov 19 REGN Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now
        Nov 19 REGN Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)
        Nov 19 REGN Regeneron: The Biotech Stock To Buy Now
        Nov 19 REGN Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3
        Nov 19 CRDF Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
        Nov 18 NKTR Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
        Nov 18 REGN FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
        Nov 15 REGN FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
        Nov 15 REGN Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S.
        Nov 15 REGN Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
        Related Industries: Biotechnology Diagnostics & Research
        Related Stock Lists: Colorectal Cancer Biopharmaceutical Biotechnology Clinical Development Drugs Immunology Medicine Nektar Therapeutics Pain Pharmaceutical Acute Myeloid Leukemia Acute Pain Adenosine Advanced Solid Tumors Aminoglycoside Angiogenesis Anti Infectives Antibiotics Antibodies Antineoplastic Drugs
        Metastatic Colorectal Cancer

        Metastatic colorectal cancer is a type of cancer that has spread from the colon or rectum to other parts of the body, such as the liver, lungs, or other organs. It is the most advanced stage of colorectal cancer and is often difficult to treat. Symptoms of metastatic colorectal cancer can include abdominal pain, fatigue, weight loss, and changes in bowel habits. Treatment options may include chemotherapy, radiation therapy, and/or surgery.

        Browse All Tags